Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

We recently published a list of the 10 Worst Performing Stocks in S&P 500 in 2024. In this article, we are going to take a ...

Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...